No big accounts are coming back. Ammon is trying, but since all clients were questioned in the Ammon Foundation and NJ Medicaid Audit investigations, they are not very happy with Ammon. SH and EH are trying to get them back, but it will be a tough sell. Also building must be sold as a condition of Ammon exiting bankruptcy. Ammon is like all other labs since COVID and NJ cuts- in a slow death! spiral They may turn a profit but 20% on $3m in revenue is a lot lower than 40% on $50m in revenue. It is a bad market for all labs right now. Multiple NJ Tox labs are for sale, everyone is down about 50% in revenue and the volume has not rebounded to pre-COVID numbers. TrueTox barely hanging on (NJ revenue of about $6m with claims holdback due to NJ Comptroller Audit) , Med Screen owners want out (revenue of about $5.5m), Clarity not sure what is happening (revenue of about $4m), RDX sold to Xeron (lost NJ Medicaid, very low revenue), SDX sold to Mako (losing clients due to billing/compliance issues) and Ammon is coming out of bankruptcy (about $3m revenue). Out of state tox labs doing business in NJ are down about 50% from NJ revenue. Bio-Reference is down about 35% overall in their post-COVID revenue and are in big trouble. It is an absolute mess in NJ. If NJ is not careful, the only labs left will be L & Q. The lab industry future is not bright, especially in NJ!